Orchid Pharma Q2 FY27: revenue up 76.3% to ₹341 Cr, net profit ₹29 Cr
Results · 17 Nov 2026 · Orchid Pharma (ORCHPHARMA)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 341 | +76.3% |
| Operating profit | 24 | - |
| Net profit | 29 | - |
In Q2 FY27, revenue from operations grew approximately 14% year-on-year to INR341 crores, gross margin rose to around 39%, and EBITDA grew 148% to INR52 crores.
Q2 FY27 profit after tax was INR28.6 crores despite a nearly 30% year-on-year rise in fuel and energy costs and two one-time accounting items of INR5 crores each.
EXBLIFEP royalty and milestone receipts reached an annual run rate of $3 million to $4 million, with recent licensing deals signed for Russia and Latin America.
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.